Americas

Europe

Austria (DE | EN)

Belgium (NL | FR | EN)

Bulgaria (EN)

Croatia (EN)

Cyprus (EN)

Czech Republic (EN)

Denmark (EN)

Estonia (EN)

Finland (EN)

France (FR | EN)

Germany (DE | EN)

Greece (EN)

Hungary (EN)

Ireland (EN)

Italy (EN)

Latvia (EN)

Liechtenstein (DE | EN)

Lithuania (EN)

Luxembourg (EN | FR | DE)

Malta (EN)

Netherlands (NL | EN)

Norway (EN)

Poland (EN)

Portugal (EN)

Romania (EN)

Slovakia (EN)

Slovenia (EN)

Spain (EN)

Sweden (EN)

Switzerland (DE | FR | EN)

Turkey (EN)

United Kingdom (EN)

Other Europe

Asia Pacific

Australia (EN)

China [Hong Kong] (EN)

China [Mainland] (ZH)

India (EN)

Indonesia (EN)

Japan (JA | EN)

Korea (South) (KO | EN)

Malaysia (EN)

New Zealand (EN)

Philippines (EN)

Singapore (EN | ZH)

Taiwan (ZH_TW | EN)

Thailand (EN)

Vietnam (EN)

Other Asia Pacific

Africa & Middle East

ABL Family Kinase Inhibitors

ABL kinase (Abelson tyrosine-protein kinase) family includes ABL1 and ARG (ABL2). ABL is said to be deeply involved in chronic myelocytic leukemia (CML) through becoming BCR-ABL fusion gene due to genetic abnormality caused by chromosomal translocation. Imatinib Mesylate (Product No. I0936), which inhibits tyrosine kinase activity of BCR-ABL protein has been used as therapeutic agent for CML).